Acurx Pharmaceuticals, Inc. To Present at The Market Movers Investor Summit
Rhea-AI Summary
Acurx Pharmaceuticals (NASDAQ: ACXP) will present at the Market Movers Investor Summit on Tuesday, May 5, 2026 at 5:20 PM ET at the historic Bank of New York, 48 Wall Street, New York.
David P. Luci, President and CEO, is scheduled to give the company presentation. Attendance requires an invitation via the summit website.
Positive
- None.
Negative
- None.
News Market Reaction – ACXP
In the Apr 27 session, ACXP gained 2.53%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Apr 20 | Earnings call notice | Neutral | -0.8% | Scheduled first quarter 2026 results call and business update announcement. |
| Apr 16 | Offering closing | Negative | -4.4% | Closed registered direct offering and concurrent private placement of warrants. |
| Apr 16 | Equity offering launch | Negative | -19.7% | Announced registered direct equity offering and concurrent warrant private placement. |
| Mar 30 | Patent grant | Positive | -6.9% | Korean patent granted for DNA Polymerase IIIC inhibitors and ACX‑375C program. |
| Mar 13 | Earnings and update | Neutral | -22.6% | Reported full-year 2025 results and clinical/business update including ibezapolstat data. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent ACXP news, including financings and corporate updates, has often been followed by negative 24-hour price reactions, with positive patent news notably selling off.
Over the last few months, ACXP has reported multiple financings, corporate updates, and clinical/patent milestones. An equity offering in mid‑April 2026 (news IDs 1041199 and 1040800) and related 8‑K/424B5 filings coincided with notable share price declines. Earlier, a Korean patent grant for DNA Polymerase IIIC inhibitors (1032877) and full‑year 2025 results and business update (1026668) also saw negative next‑day moves. Against this backdrop, today’s investor summit appearance is a non-fundamental visibility event rather than a major financial or clinical catalyst.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Staten Island, New York--(Newsfile Corp. - April 27, 2026) - Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("we" or "Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, today announced that it will be participating in the Market Movers Investor Summit on Tuesday May 5, 2026. The presentation will take place at 05:20 PM ET at the historic Bank of New York. David P. Luci, President & Chief Executive Officer, will be giving the presentation.
The Market Movers Investor Summit is a premier, high-access event on Wall Street. The inaugural program features fireside chats with Alex Rodriguez, Chairman and CEO of A-Rod Corp, and Grant Cardone, CEO of Cardone Capital, in addition company presentations and one-on-one meetings throughout the day.
Event Details:
- Summit Dates: May 5, 2026
- Company Presentation: Tuesday, May 5, 2026
- Time: 05:20 PM ET
- Location: 48 Wall Street, New York, NY (The original Bank of New York)
Request an invitation to attend at www.marketmoverssummit.com.
Summary of Market Movers Investor Summit
The 2026 Market Movers Investor Summit begins on May 4th with a kickoff party at the legendary Delmonico's, followed by a full day of programming on May 5th. The summit brings together public and private company executives, fund managers, and family offices for a focused, high-caliber experience. The agenda includes company presentations and one-on-one meetings, exclusive fireside chats and keynote sessions, a pop-up lunch from the legendary Katz Delicatessen, and a surprise musical guest.
About Acurx Pharmaceuticals, Inc.
Acurx Pharmaceuticals is a late-stage biopharmaceutical company focused on developing a new class of small molecule antibiotics for difficult-to-treat bacterial infections. The Company's approach is to develop antibiotic candidates with a Gram-positive selective spectrum (GPSS®) that blocks the active site of the Gram+ specific bacterial enzyme DNA polymerase IIIC (pol IIIC), inhibiting DNA replication and leading to Gram-positive bacterial cell death. Its R&D pipeline includes antibiotic product candidates that target Gram-positive bacteria, including Clostridioides difficile, methicillin- resistant Staphylococcus aureus (MRSA), vancomycin resistant Enterococcus (VRE), drug- resistant Streptococcus pneumoniae (DRSP) and B. anthracis (anthrax; a Bioterrorism Category A Threat-Level pathogen).
Acurx's lead product candidate, ibezapolstat, for the treatment of C. difficile Infection (CDI) is Phase 3 ready to advance to international clinical trials subject to obtaining appropriate financing. The Company recently announced the launch of a ground-breaking clinical trial with ibezapolstat in patients with multiply-recurrent CDI (rCDI) that has the potential to shift the paradigm of treatment and prevention of rCDI from two agents to one. This new clinical trial in rCDI begins with an open-label pilot trial to gain experience with IBZ in patients with multiply-recurrent CDI with at least 3 episodes of CDI within the past 12 months. This will inform elements of a planned active-controlled, Phase 3 registration trial in the rCDI indication to be implemented following favorable results from the open-label 20 patient trial. Upon subsequent successful completion of the Ph3 pivotal rCDI trial, and per the operative FDA procedure, Acurx plans to request FDA approval for treatment and prevention of rCDI under the FDA's Limited Population Pathway for Antibacterial and Antifungal Drugs (Guidance for Industry, 2020).
The Company's preclinical pipeline includes development of an oral product candidate for treatment of ABSSSI (Acute Bacterial Skin and Skin Structure Infections), upon which a development program for treatment of inhaled anthrax is being planned in parallel.
To learn more about Acurx Pharmaceuticals and its product pipeline, please visit www.acurxpharma.com.
Forward-Looking Statements
Any statements in this press release about our future expectations, plans and prospects, including statements regarding our strategy, future operations, prospects, plans and objectives, and other statements containing the words "believes," "anticipates," "plans," "expects," and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding the ability of the Company to consummate the offering, the exercise of the short-term warrants prior to their expiration, the satisfaction of the closing conditions of the offering, and the use of proceeds therefrom. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: market and other conditions, and other risks and uncertainties described in the Company's annual report filed with the Securities and Exchange Commission on Form 10-K for the year ended December 31, 2025, and in the Company's subsequent filings with the Securities and Exchange Commission. Such forward-looking statements speak only as of the date of this press release, and Acurx disclaims any intent or obligation to update these forward-looking statements to reflect events or circumstances after the date of such statements, except as may be required by law.
Investor Contact:
Acurx Pharmaceuticals, Inc.
David P. Luci, President & Chief Executive Officer
Tel: 917-533-1469
Email: davidluci@acurxpharma.com
Source: Acurx Pharmaceuticals, Inc.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/294135